Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16075278 | 0.96 | BTK (0.73) | BTK | |
| SCHEMBL16075268 | 0.93 | BTK (0.72) | BTKEGFRTEC | |
| SCHEMBL16075279 | 0.87 | BTK (0.66) | BTKEGFRTEC | |
| SCHEMBL16075280 | 0.86 | BTK (0.61) | BTKEGFR | |
| SCHEMBL16075334 | 0.85 | BTK (0.53) | BTK | |
| SCHEMBL16075267 | 0.85 | BTK (0.69) | BTK | |
| SCHEMBL19909771 | 0.84 | BTK (0.55) | BTK | |
| SCHEMBL19909657 | 0.83 | BTK (0.66) | BTKEGFRTEC | |
| SCHEMBL16075285 | 0.82 | BTK (0.58) | BTK | |
| SCHEMBL15472610 | 0.82 | BTK (1.00) | BTKEGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970163-B1 | 5-THIAZOLECARBOXAMIDE DERVATIVES AND THEIR USE AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-8895750-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895750-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| WO-2014151620-A1 | 5-THIAZOLECARBOXAMIDE DERVATIVES AND THEIR USE AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275012-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275012-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275012-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885EGFR 307/4885TEC 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.